HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

Gynecologic

Gynecologic

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

7 Clinical Trials
Gynecologic Phase III Accepting Patients
nct/study# NCT00980954 / RTOG-0724-0724

Phase III Randomized Study Of Concurrent Chemotherapy And Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Learn More
Gynecologic Phase III Active
nct/study# NA / MK3475-B96

A Phase 3, Randomized, Double-Blind Study Of Pembrolizumab Versus Placebo In Combination With Paclitaxel With Or Without Bevacizumab For The Treatment Of Platinum-Resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-Ov65)

Learn More
Gynecologic Phase III Active
nct/study# NCT04095364 / NRG-GY019

A Randomized Phase III, Two-Arm Trial Of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy In Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma Of The Ovary Or Peritoneum

Learn More
Gynecologic Phase III Active
nct/study# NCT04214067 / NRG-GY020-JTCC

NRG Oncology, Protocol: NRG-GY020, PI: Dr. Mcnamara, Title: A Phase III Randomized Trial Of Radiation +/- Mk-3475 (Pembrolizumab) For Actively Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (Dmmr) Endometrioid Endometrial Cancer

Learn More
Gynecologic Phase I/II Accepting Patients
nct/study# NCT03393884 / 201-17-201

A Phase I/II Study Evaluating The Dosing, Safety, Efficacy, And Biological Activity Of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Neoadjuvant Chemotherapy (NACT) In Patients Actively Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer

Learn More
Gynecologic Phase I Accepting Patients
nct/study# NCT03704467 / RESEARCH-DEVELOPMENT-MS201943-0029

A Phase Ib Safety Run-In And Randomized Phase II, Open-Label Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of M6620 In Combination With Avelumab And Carboplatin In Comparison To Standard Of Care Therapy In Participants With Parpi-Resistant Recurrent Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.